Webinar: Unmatched Viral Particle Analysis in Vaccine and Gene Therapy Development
Sponsored by: Vironova
- Viral Vector Particles
- Traditional Assays
Date: 18 October
Days to go: 26
Time: 3PM London/10AM New York
The number of gene therapy applications based on viral vectors are growing and small-scale manufacturing processes are increasingly requiring scaling up to commercial processes.
Numerous challenges must be overcome in scaling-up to full commercial production Undesired outcomes may slip through if not monitored carefully during the process development.
In this webinar we will show how MiniTEM can reveal powerful data where traditional assays have limitations.
With the introduction of the MiniTEM™ system, transmission electron microscopy has become an accessible method for routine testing in bioprocessing. Through automated image acquisition, particle detection and classification MiniTEM can provide both high-resolution images and reliable quantitative data in a very short turnaround time.
Register to this webinar to learn more.
Head of EM Services
Dr. Josefina Nilsson joined Vironova in 2007, at an early phase of the company. She has since then served to shape the company’s evolving services and solutions related to sub-visible particle characterization for the pharmaceutical industry.
Vironova is a Swedish company offering unique services for nanoparticle -characterization and viral clearance testing together with hardware and software solutions for advanced electron microscopy image analysis.
Key Learning Objectives
- How MiniTEM automatically can: Screen the viral particle morphology status throughout the process
- How MiniTEM automatically can: Determine sample purity
- How MiniTEM automatically can: Detect aggregates
- How MiniTEM automatically can: Compare the portion of intact versus broken viral particles
- How MiniTEM automatically can: Indicate virus titer
- Senior Scientist
- Analytics Scientist
- Formulation Scientist
- Process Development